Platelet Microvesicles, Inflammation, and Coagulation Markers: A Pilot Study

Hematol Rep. 2023 Dec 4;15(4):684-695. doi: 10.3390/hematolrep15040069.

Abstract

Background: Platelet "Microvesicles" (MVs) are studied for their role in blood coagulation and inflammation. The study aimed to establish if MVs are related to age, plasma levels of inflammation, coagulation, and fibrinolysis markers in healthy individuals.

Methods: We prospectively enrolled volunteers aged over 18 years. MVs, plasma levels of C-reactive protein (CRP), Interleukin 6 (IL-6), Interleukin 10 (IL-10), Interleukin 17 (IL-17), and transforming growth factor β (TGF-β), fibrinogen, plasminogen activator inhibitor-1 (PAI-1), von Willebrand factor (VWF), homocysteine, factor VII (FVII), thrombin activatable fibrinolysis inhibitor (TAFI), and Protein S were tested.

Results: A total of 246 individuals (median age 65 years ("IQR"54-72)) were evaluated. Both univariate analysis and logistic regression models showed that MVs positively correlate with age, CRP, IL-6, IL-10, IL-17, TGF-β, fibrinogen, PAI-1, VWF, FVII, and homocysteine, while inversely correlating with TAFI and Protein S. The ROC curve analysis performed to identify a cut off for MV values (700 kMP) showed a good accuracy with over-range cytokines fibrinolysis factor and coagulation markers.

Conclusions: To the best of our knowledge, this study is the first to correlate MVs with an entire panel of cardiovascular risk factors in healthy individuals. A future possible role of MVs in screening exams is suggested.

Keywords: C-reactive protein (CRP); Interleukin 10 (IL-10); Interleukin 17 (IL-17); Interleukin 6 (IL-6); Protein S; factor VII (FVII); fibrinogen; homocysteine; microparticles; microvesicles; plasminogen activator inhibitor-1 (PAI-1); thrombin activatable fibrinolysis inhibitor (TAFI); transforming growth factor β (TGF-β); von Willebrand factor (VWF).